SPY334.57+0.24 0.07%
DIA274.62+0.72 0.26%
IXIC11,010.98-97.09 -0.87%
Epizyme's (EPZM) Q2 Earnings and Revenues Miss Estimates
Epizyme (EPZM) reports a wider-than-expected loss and misses sales estimates in the second quarter of 2020.
Zacks · 2d ago
Morgan Stanley Maintains Overweight on Epizyme, Lowers Price Target to $29
Morgan Stanley maintains Epizyme (NASDAQ:EPZM) with a Overweight and lowers the price target from $31 to $29.
Benzinga · 2d ago
Epizyme Inc (EPZM) Q2 2020 Earnings Call Transcript
On the call with me is Rob Bazemore, CEO; Matt Ros, Chief Strategy and Business Officer; and Paolo Tombesi, Chief Financial Officer. Dr. Shefali Agarwal, Chief Medical Officer will join us for the Q&A session.
Motley Fool · 3d ago
Epizyme shares are trading lower after the company reported worse-than-expected Q2 sales results.
Benzinga · 3d ago
Epizyme EPS misses by $0.01, misses on revenue
Epizyme (NASDAQ:EPZM): Q2 GAAP EPS of -$0.58 misses by $0.01. Revenue of $2.47M (-58.1% Y/Y) misses by $1.99M. Press Release
seekingalpha · 3d ago
Epizyme (EPZM) Reports Q2 Loss, Misses Revenue Estimates
Epizyme (EPZM) delivered earnings and revenue surprises of -3.57% and -47.12%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 4d ago
Recap: Epizyme Q2 Earnings
Shares of Epizyme (NASDAQ:EPZM) were unchanged after the company reported Q2 results.Quarterly Results Earnings per share decreased 9.43% over the past year to ($0.58), which beat the estimate of ($0.61).Revenue of $2,467,000 decreased by 58.19% from the same
Benzinga · 4d ago
Epizyme Q2 EPS $(0.58) Beats $(0.61) Estimate, Sales $2.47M Miss $4.30M Estimate
Epizyme (NASDAQ:EPZM) reported quarterly losses of $(0.58) per share which beat the analyst consensus estimate of $(0.61) by 4.92 percent. This is a 9.43 percent decrease over losses of $(0.53) per share from the same
Benzinga · 4d ago
Epizyme Reports Business Progress and Second Quarter 2020 Financial Results
Epizyme Reports Business Progress and Second Quarter 2020 Financial Results
Business Wire · 4d ago
Epizyme Announces Date of Second Quarter 2020 Financial Results and Participation at 2020 Wedbush PacGrow Healthcare Virtual Conference
Epizyme, Inc. (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that management will host a conference call and webcast to discuss its second quarter 2020 financ
Business Wire · 07/28 10:30
Were Hedge Funds Right About Epizyme Inc (EPZM)?
How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds
Insider Monkey · 07/16 22:31
Epizyme A Buy For Tazverik And Epigenetic Platform
Seeking Alpha - Article · 07/01 05:37
Insider Weekends: Harold Hamm Buys More Of Continental Resources
Seeking Alpha - Article · 06/29 06:03
Insider Buying: The Epizyme, Inc. (NASDAQ:EPZM) Independent Chairman Just Bought 49% More Shares
Simply Wall St. · 06/28 14:31
Notable Insider Buys: Continental Resources, Fox, Groupon And More
Insider buying can be an encouraging signal for potential investors. Some C-suite insiders were among those recently adding to stakes. Biotechs, an energy company and a media giant saw insider buying.
Benzinga · 06/27 19:17
Aptinyx PTSD Trial And Other News: The Good, Bad And Ugly Of Biopharma
Seeking Alpha - Article · 06/21 07:11
Dow gives up early gains as Apple says it will re-close stores and W.H.O. says coronavirus has entered new and dangerous phase
MarketWatch · 06/19 20:01
Epizyme Gets FDA Nod for Tazverik sNDA in Follicular Lymphoma
Zacks · 06/19 15:19
Epizyme's shares fall after receiving new FDA approval for cancer drug
MarketWatch · 06/19 15:02
Are Options Traders Betting on a Big Move in Epizyme (EPZM) Stock?
Zacks · 06/19 14:41